Reports positive early clinical experience from first and only clinically validated, extracellular protein degraders using Biohaven's proprietary MoDE™ and next-generation, highly selective TRAP™ ...
PURCHASE, N.Y., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (CGTX) (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results